FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study
Abstract Background Treatment of opiate addiction with opiate substitution treatment (e.g. methadone) is beneficial. However, some individuals desire or would benefit from abstinence but there are limited options to attenuate problems with opiate withdrawal. Preclinical and preliminary clinical evid...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | Trials |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13063-022-06821-9 |
| _version_ | 1811250018414231552 |
|---|---|
| author | L. M. Paterson D. Barker S. Cro P. Mozgunov R. Phillips C. Smith L. Nahar S. Paterson A. R. Lingford-Hughes |
| author_facet | L. M. Paterson D. Barker S. Cro P. Mozgunov R. Phillips C. Smith L. Nahar S. Paterson A. R. Lingford-Hughes |
| author_sort | L. M. Paterson |
| collection | DOAJ |
| description | Abstract Background Treatment of opiate addiction with opiate substitution treatment (e.g. methadone) is beneficial. However, some individuals desire or would benefit from abstinence but there are limited options to attenuate problems with opiate withdrawal. Preclinical and preliminary clinical evidence suggests that the GABA-B agonist, baclofen, has the desired properties to facilitate opiate detoxification and prevent relapse. This study aims to understand whether there are any safety issues in administering baclofen to opioid-dependent individuals receiving methadone. Methods Opiate-dependent individuals (DSM-5 severe opioid use disorder) maintained on methadone will be recruited from addiction services in northwest London (NHS and third sector providers). Participants will be medically healthy with no severe chronic obstructive pulmonary disease or type 2 respiratory failure, no current dependence on other substances (excluding nicotine), no current severe DSM-5 psychiatric disorders, and no contraindications for baclofen or 4800 IU vitamin D (placebo). Eligible participants will be randomised in a 3:1 ratio to receive baclofen or placebo in an adaptive, single-blind, ascending dose design. A Bayesian dose-escalation model will inform the baclofen dose (10, 30, 60, or 90 mg) based on the incidence of ‘dose-limiting toxicity’ (DLT) events and participant-specific methadone dose. A range of respiratory, cardiovascular, and sedative measures including the National Early Warning Score (NEWS2) and Glasgow Coma Scale will determine DLT. On the experimental day, participants will consume their usual daily dose of methadone followed by an acute dose of baclofen or placebo (vitamin D3) ~ 1 h later. Measures including oxygen saturation, transcutaneous CO2, respiratory rate, QTc interval, subjective effects (sedation, drug liking, craving), plasma levels (baclofen, methadone), and adverse events will be obtained using validated questionnaires and examinations periodically for 5 h after dosing. Discussion Study outcomes will determine what dose of baclofen is safe to prescribe to those receiving methadone, to inform a subsequent proof-of-concept trial of the efficacy baclofen to facilitate opiate detoxification. To proceed, the minimum acceptable dose is 30 mg of baclofen in patients receiving ≤ 60 mg/day methadone based on the clinical experience of baclofen’s use in alcoholism and guidelines for the management of opiate dependence. Trial registration Clinicaltrials.gov NCT05161351. Registered on 16 December 2021. |
| first_indexed | 2024-04-12T15:56:40Z |
| format | Article |
| id | doaj.art-ecd4bbd2fe8048a9a293bf4495800950 |
| institution | Directory Open Access Journal |
| issn | 1745-6215 |
| language | English |
| last_indexed | 2024-04-12T15:56:40Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj.art-ecd4bbd2fe8048a9a293bf44958009502022-12-22T03:26:20ZengBMCTrials1745-62152022-10-0123111510.1186/s13063-022-06821-9FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic studyL. M. Paterson0D. Barker1S. Cro2P. Mozgunov3R. Phillips4C. Smith5L. Nahar6S. Paterson7A. R. Lingford-Hughes8Division of Psychiatry, Department of Brain Sciences, Imperial College LondonDivision of Psychiatry, Department of Brain Sciences, Imperial College LondonImperial Clinical Trials Unit, Imperial College LondonMRC Biostatistics Unit, University of CambridgeImperial Clinical Trials Unit, Imperial College LondonImperial Clinical Trials Unit, Imperial College LondonToxicology Unit, Imperial College LondonToxicology Unit, Imperial College LondonDivision of Psychiatry, Department of Brain Sciences, Imperial College LondonAbstract Background Treatment of opiate addiction with opiate substitution treatment (e.g. methadone) is beneficial. However, some individuals desire or would benefit from abstinence but there are limited options to attenuate problems with opiate withdrawal. Preclinical and preliminary clinical evidence suggests that the GABA-B agonist, baclofen, has the desired properties to facilitate opiate detoxification and prevent relapse. This study aims to understand whether there are any safety issues in administering baclofen to opioid-dependent individuals receiving methadone. Methods Opiate-dependent individuals (DSM-5 severe opioid use disorder) maintained on methadone will be recruited from addiction services in northwest London (NHS and third sector providers). Participants will be medically healthy with no severe chronic obstructive pulmonary disease or type 2 respiratory failure, no current dependence on other substances (excluding nicotine), no current severe DSM-5 psychiatric disorders, and no contraindications for baclofen or 4800 IU vitamin D (placebo). Eligible participants will be randomised in a 3:1 ratio to receive baclofen or placebo in an adaptive, single-blind, ascending dose design. A Bayesian dose-escalation model will inform the baclofen dose (10, 30, 60, or 90 mg) based on the incidence of ‘dose-limiting toxicity’ (DLT) events and participant-specific methadone dose. A range of respiratory, cardiovascular, and sedative measures including the National Early Warning Score (NEWS2) and Glasgow Coma Scale will determine DLT. On the experimental day, participants will consume their usual daily dose of methadone followed by an acute dose of baclofen or placebo (vitamin D3) ~ 1 h later. Measures including oxygen saturation, transcutaneous CO2, respiratory rate, QTc interval, subjective effects (sedation, drug liking, craving), plasma levels (baclofen, methadone), and adverse events will be obtained using validated questionnaires and examinations periodically for 5 h after dosing. Discussion Study outcomes will determine what dose of baclofen is safe to prescribe to those receiving methadone, to inform a subsequent proof-of-concept trial of the efficacy baclofen to facilitate opiate detoxification. To proceed, the minimum acceptable dose is 30 mg of baclofen in patients receiving ≤ 60 mg/day methadone based on the clinical experience of baclofen’s use in alcoholism and guidelines for the management of opiate dependence. Trial registration Clinicaltrials.gov NCT05161351. Registered on 16 December 2021.https://doi.org/10.1186/s13063-022-06821-9OpiateAddictionDependenceGABA-BBaclofenMethadone |
| spellingShingle | L. M. Paterson D. Barker S. Cro P. Mozgunov R. Phillips C. Smith L. Nahar S. Paterson A. R. Lingford-Hughes FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study Trials Opiate Addiction Dependence GABA-B Baclofen Methadone |
| title | FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study |
| title_full | FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study |
| title_fullStr | FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study |
| title_full_unstemmed | FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study |
| title_short | FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study |
| title_sort | forwards 1 an adaptive single blind placebo controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone maintenance treatment a pharmacokinetic pharmacodynamic study |
| topic | Opiate Addiction Dependence GABA-B Baclofen Methadone |
| url | https://doi.org/10.1186/s13063-022-06821-9 |
| work_keys_str_mv | AT lmpaterson forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT dbarker forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT scro forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT pmozgunov forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT rphillips forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT csmith forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT lnahar forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT spaterson forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy AT arlingfordhughes forwards1anadaptivesingleblindplacebocontrolledascendingdosestudyofacutebaclofenonsafetyparametersinopioiddependenceduringmethadonemaintenancetreatmentapharmacokineticpharmacodynamicstudy |